iScale Oligos DNA and siRNA are milligram and gram quantities of custom DNA and siRNA oligonucleotides manufactured to meet specialized needs.
Milligram and gram quantities of Custom DNA Oligos are for in vivo, high-throughput, and commercial projects (life science research tools, molecular diagnostics, and laboratory developed tests). For iScale quantities of NGS adapters, please see our Next-Gen Sequencing Oligos product
For anything marked as ‘Inquire’ below or If you have needs that are different from the other general specifications presented, please send a request to email@example.com.
This quality culture is integrated into all aspects of our business. Key components of our QMS include:
Each component drives quality assurance, and for verification, we routinely host rigorous registrar, internal, and customer audits.
Milligram and gram quantities of MISSION in-vivo-quality siRNA are superior for RNAi research in animals. We also manufacture other types of RNA, including miRNA and single-stranded RNA.
For anything marked as ‘Inquire’ below or If you have needs that are different from the other general specifications presented, please send a request to firstname.lastname@example.org.
*Depending on manufacturing site, PAGE may be used to assess siRNA duplexes.
We teamed up with Bioo Scientific (now PerkinElmer) to validate our MISSION in-vivo-quality siRNA (see article in Drug Discovery & Development—Aug 1, 2008).
In these experiments, H1155luc cells were injected into NOD/SCID mice. Tumors formed and were injected with luciferase-specific siRNA or non-targeting in-vivo-quality siRNA formulated in MaxSuppressor™ In Vivo RNA-LANCEr II. After 24 hours, D-luciferin solution was injected, and the animals were imaged using the NightOWL II LB 983 instrument from Berthold Technologies. Animals treated with luciferase-specific siRNA showed significant reduction of luciferase activity while non-targeting siRNA-treated animals were positive for luminescence (Figure 1). These data demonstrate the effectiveness of in-vivo-quality siRNA formulated in MaxSuppressor™ In Vivo RNA-LANCEr II in vivo delivery agent.
Figure 1.Luciferase-specific siRNA treated animal on the left; non-targeting siRNA treated animal on the right
At 72 hours post-injection, the tumors were removed, and the protein was extracted and normalized using a Bradford assay. Luciferase concentrations were assayed using a Luciferase ELISA. Protein reduction is represented relative to a non-targeting RNAi agent treated animal. Luciferase activity was reduced by two-fold in the tumors (Figure 2).
Figure 2.Each replicate is a different mouse
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.